Is Cytodyn Inc halal to invest in?

As of July 2026, Cytodyn Inc 296.BE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Cytodyn Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cytodyn Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Cytodyn Inc?

Muslim investors may consider investing in Cytodyn Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cytodyn Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Cytodyn Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cytodyn Inc updated?

The Shariah compliance status of Cytodyn Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cytodyn Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cytodyn Inc?

You can check the latest Shariah compliance status of Cytodyn Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Cytodyn Inc 296.BE

Last Updated: Dec 19, 12:00 AM·BE

296.BE Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Cytodyn Inc is classified as not halal.

NOT HALAL

Report Source: 2025 1st Quarter Report

Cytodyn Inc. Stock Analysis 296.BE

Germany Health Care Small Cap Report: Q1, 2025

CytoDyn, Inc. is a clinical-stage biotechnology company, which focuses on the clinical development of innovative treatments for multiple therapeutic indications based on its product candidate, leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5. The company is headquartered in Vancouver Washington, Washington and currently employs 13 full-time employees. The company went IPO on 2005-11-17. The firm is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The company has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The firm has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses, such as metabolic dysfunction-associated steatohepatitis. The company has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

Key Statistics of Cytodyn Inc (296.BE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.18€0.25

Today's Open

€0.25

Volume

2640.00

P/E Ratio (TTM)

77.71

Financial Metrics & Statements of Cytodyn Inc (296.BE)

Super Investors Invested in Cytodyn Inc (296.BE)

FAQ's for Cytodyn Inc (296.BE)

As of July 2026, Cytodyn Inc 296.BE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cytodyn Inc using these criteria to determine its compliance status.
Muslim investors may consider investing in Cytodyn Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
Musaffa determines the Shariah status of Cytodyn Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
The Shariah compliance status of Cytodyn Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
You can check the latest Shariah compliance status of Cytodyn Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.